Month: March 2024
ATLANTA and LONDON, March 26, 2024 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq: DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that Charlotte, NC-based Bahr Transportation, a freight brokerage specializing in the movement of perishable goods across the U.S. and Canada, is using the cloud-based Descartes Aljex™ transportation management system (TMS), together with Descartes MacroPoint™ real-time transportation visibility platform (RTTVP) and automated capacity sourcing solutions. The integrated solutions allow Bahr Transportation to cover more customer freight while providing full visibility across the supply chain to enhance shipper and carrier relationships.
“We specialize in refrigerated shipments of temperature-sensitive perishable goods, which means we...
e.GO Announces Nasdaq Delisting Notice
Written by Customer Service on . Posted in Public Companies.
AACHEN, Germany, March 26, 2024 (GLOBE NEWSWIRE) — Next.e.GO N.V. (NASDAQ:EGOX) (“e.GO”) today announced that on March 25, 2024 the Company received a Staff determination letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company of the Staff’s determination to delist the Company’s securities because the Company’s securities have had a closing bid price below $0.10 for ten consecutive trading days, which triggers a notice of delisting pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”).
In addition to the $0.10 Rule delisting notice, the Company also currently fails to satisfy the requirement that the closing bid price of its securities remain at $1.00 or higher as required by Nasdaq Listing Rule 5810(c)(3)(A) (the “Minimum Bid Price...
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Data readout from Phase 3 clinical trial in the People’s Republic of China (“PRC”) evaluating F351 for the treatment of CHB-associated liver fibrosis expected by early 2025
U.S. Phase 2a clinical trial evaluating F351 for the treatment of NASH-associated liver fibrosis planned for 2025
Appointed Dr. Han Ying as Chief Executive Officer
Acquired indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd) as part of business combination agreement with GNI
Cash and cash equivalents totaled $33.5 million as of December 31, 2023
SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) — Gyre Therapeutics, Inc. (“Gyre”) (Nasdaq: GYRE), a clinical-stage biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced financial results for...
Parsons Continues US Air Force Research and Development Support Through $28 Million Task Order
Written by Customer Service on . Posted in Public Companies.
CHANTILLY, Va., March 26, 2024 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) announced today that the company was awarded a $28 million cost-plus-fixed-fee contract to provide intelligence, surveillance, and reconnaissance command and control and space software baselines for the Air Force Research Laboratory’s (AFRL) Global Application Research, Development, Engineering, and Maintenance (GARDEM) program. The contract includes one three-year performance period and extends Parsons’ portfolio of work supporting the Department of Defense (DOD) and Intelligence Community (IC), delivering exquisite software capabilities across the all-domain battlespace.
“Parsons delivers value for national security customers like the U.S. Air Force by integrating technologies, transforming data, and customizing site-specific capabilities to meet...
UTStarcom Announces Changes to Its Board of Directors
Written by Customer Service on . Posted in Public Companies.
HANGZHOU, China, March 26, 2024 (GLOBE NEWSWIRE) — UTStarcom (“UT” or the “Company”) (NASDAQ: UTSI), a global telecommunications infrastructure provider, today announced changes to the Board of Directors and appointed Dr. Yong Wang as the Company’s new independent director, effective Mar 21, 2024.
Dr. Jintong Lin resigned from the Company’s board of Directors, as well as the chairman of the Company’s Nominating and Corporate Governance Committee, member of Audit Committee and Compensation Committee on Mar 21, 2024, which he had held since September 2019. Dr. Yong Wang was appointed as an independent director of the Company and the positions in various committees vacated by Dr. Lin, effective Mar 21, 2024.
Mr. Ning Shan, UTStarcom’s Chairman of Board of Directors, commented, “On behalf of the Company and the board of directors, we...
Valeura Energy Inc.: Fourth Quarter and Year-end 2023 Results
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Record Results in 2023 from First Year of Thailand Operations
SINGAPORE and CALGARY, Alberta, March 26, 2024 (GLOBE NEWSWIRE) — Valeura Energy Inc. (TSX:VLE, OTCQX:VLERF) (“Valeura” or the “Company”), the upstream oil and gas company with assets in the Gulf of Thailand and the Thrace Basin of Türkiye, reports its financial and operating results for the three month period and year ended December 31, 2023.
The complete reporting package for the Company, including the audited financial statements and associated management’s discussion and analysis (“MD&A”) and the 2023 annual information form (“AIF”), are being filed on SEDAR+ at www.sedarplus.ca and posted to the Company’s website at www.valeuraenergy.com.
2023 HighlightsClosed the Mubadala Acquisition(1) for...
Festi hf: Festi acquisition of all shares in Lyfja hf. – Request for conciliation talks with the Icelandic Competition Authority.
Written by Customer Service on . Posted in Public Companies.
Reference is made to Festi’s announcement, published on the 18th of March 2024, regarding the preliminary conclusions in the Icelandic Competition Authority’s investigation into the competitive effects of Festi’s purchase on the entire share capital of Lyfja hf. It is stated therein that the merger will, based on the current state of the investigation, require intervention by the Icelandic Competition Authority.
Festi has now submitted a response to the Icelandic Competition Authority‘s preliminary conclusions where Festi‘s arguments and proposals for remedies are presented. The response formally requests a conciliation talks with the Icelandic Competition Authority on possible remedies associated with the aquisition. Festi‘s request is now under evaluation by the Icelandic Competition Authority.
Accordingly, the Competition Authority’s...
The results of business activity of ŽEMAITIJOS PIENAS, AB group in 2023, excluding audit
Written by Customer Service on . Posted in Public Companies.
In 2023, consolidated turnover (excluding audit) of ŽEMAITIJOS PIENAS, AB group amounts to 278 million EUR that, if to be compared with the year 2022, has increased by 5,55 %.
Net profit (as without audit) of ŽEMAITIJOS PIENAS, AB group in the year 2023, makes 7,7 % of the turnover.The person authorized to provide additional information:
Arnas MatuzasHead of LegalE-mail: a.matuzas@zpienas.lt
Kvika banki hf.: Announcement regarding reduction in share capital
Written by Customer Service on . Posted in Public Companies.
At Kvika’s AGM held on 21 March 2024 the meeting approved to reduce the company’s share capital by ISK 58,952,375 nominal value, or the equivalent of 58,952,375 shares, from ISK 4,781.025,715 to ISK 4,722,073,340 nominal value, by cancelling own shares held by the company in the said amount.
These are shares that the company purchased under a formal buy-back programme in 2023.
The share capital reduction has now been registed by the register of undertakings of the Directorate of internal Revenue and the share capital amounts to nominal value of ISK 4,722,073,340.
Following the reduction the bank holds no own shares.
For further information please contact Magnús Þór Gylfason, Director of Communications and Stakeholder Relations, at magnus.gylfason@kvika.is
Result of the auction of treasury bills on 26 March 2024
Written by Customer Service on . Posted in Public Companies.
Bids, sales, stop-rates and prices are presented in the table below: ISIN
Bid Mill. kr. (nominal)
Sale
Stop-rate (per cent)
Pro-rata
Price98 19310 DKT 03/06/24 II
620
–
–
–
–98 19583 DKT 03/09/24 III
500
400
3.44
100 %
98.5498Total
1,120
400
The sale will settle 2 April 2024.
